Description:
- Prognostic biomarkers for brain tumors and immunotherapies for glioblastoma multiforme
- RNA based biotherapeutics
Abstract
USC researchers have discovered long non-coding RNAs (lncRNAs) that were aberrantly expressed specifically in GBM brains relative to normal brains. These lncRNAs had prognostic significance and could serve as prognostic biomarkers for GBM brain cancer. Overall, 18 of the top 20 lncRNA in differential expression and 8 lncRNA significant for overall survival were new discoveries that could be further developed for diagnostic purposes.
Benefit
•Novel lncRNAs in glioblastoma and astrocytoma pathogenesis discovered •Eight lncRNAs significantly linked to survival •RNA-based diagnostic potential
Market Application
Market Opportunity:
Glioblastoma multiforme (GBM) is the most lethal and aggressive form of primary brain cancer in adults. Standard therapy for GBM includes surgery, radiotherapy, and temozolomide. However, less than 5% of patients are alive after 5 years with this treatment. Therefore, there is an urgent need for new therapies or prognostic biomarkers that can help identify brain tumors early for strategic treatment.
Applications:
•Prognostic biomarkers for brain tumors and immunotherapies for glioblastoma multiforme •RNA based biotherapeutics
Publications
Ready for publication
Other
Stage of Development
- Successful identification of novel markers via next generation RNA-sequencing
- In vitro and in vivo experiments are ongoing
IP Status: US Utility Patent issued(Application 15/456,285)